Quifenadine

Quifenadine (Russian: хифенадин, trade name: Phencarol, Фенкарол) is a 2nd generation antihistamine drug, marketed mainly in post-Soviet countries.[2][3] Chemically, it is a quinuclidine derivative.

Not to be confused with quinidine.

Quifenadine

Clinical data
Trade names	Fencarol
Other names	3-Quinuclidinyldiphenylmethanol
Routes of administration	Oral (tablets), IM injection
ATC code	R06AX31 (WHO)
Legal status
Legal status	OTC (tablets), ℞-only (solution for IM injection) (RU)
Pharmacokinetic data
Bioavailability	45% (Tmax = 1 hour)[1]
Metabolism	Liver
Identifiers
IUPAC name 1-Azabicyclo[2.2.2]octan-3-yl(diphenyl)methanol
CAS Number	10447-38-8
PubChem CID	65600
ChemSpider	59041
UNII	W9A18RJ49B
KEGG	D10230
ChEMBL	ChEMBL1187694
CompTox Dashboard (EPA)	DTXSID6046187
Chemical and physical data
Formula	C20H23NO
Molar mass	293.410 g·mol^−1
3D model (JSmol)	Interactive image
SMILES OC(c1ccccc1)(c2ccccc2)C4C3CCN(CC3)C4
InChI InChI=1S/C20H23NO/c22-20(17-7-3-1-4-8-17,18-9-5-2-6-10-18)19-15-21-13-11-16(19)12-14-21/h1-10,16,19,22H,11-15H2 Key:PZMAHNDJABQWGS-UHFFFAOYSA-N

Indications

• Allergic rhinitis
• Acute and chronic urticaria
• Angioedema
• Dermatitis
• Atopic dermatitis
• Pruritus[1]

References

1. "Fencarol (quifenadine) Tablets, for Oral Use. Full Prescribing Information". State Register of Medicines (in Russian). Retrieved 4 January 2016.
2. "Quifenadine". Drugs.com. Retrieved 28 January 2014.
3. Makarov L, Balykova L, Soldatova O, Komolyatova V, Serebruany V (2010). "The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: a randomized controlled pilot trial". American Journal of Therapeutics. 17 (4): 396–401. doi:10.1097/MJT.0b013e3181a86987. PMID 19487925.